Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 70Years
All Genders
NCT06589778

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2024-11-12

124

Participants Needed

1

Research Sites

82 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.

CONDITIONS

Official Title

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to give voluntary informed consent, understand the study, and willing to complete all test procedures
  • Aged 18 to 70 years old
  • Pathologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer
  • At least one measurable lesion according to RECIST v1.1 criteria
  • ECOG performance status score of 0 or 1
Not Eligible

You will not qualify if you...

  • Presence of active or symptomatic brain metastases
  • Previous diagnosis of any other malignancy
  • Clinically symptomatic moderate to severe ascites
  • Uncontrollable or moderate or above pleural effusion or pericardial effusion
  • Received anti-tumor therapy within 4 weeks before starting study treatment
  • Uncontrolled tumor-related pain
  • Severe cardiovascular or cerebrovascular diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China, 200030

Actively Recruiting

Loading map...

Research Team

X

Xin Xu

CONTACT

Y

Yunfei Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | DecenTrialz